Prostate Cancer - Results from #23120

Metabolic and toxicological considerations of newly approved prostate cancer drugs - Abstract May 28, 2013

Strategies for managing ACTH dependent mineralocorticoid excess induced by abiraterone - Abstract May 28, 2013

Prostate-specific antigen bounce after high-dose-rate monotherapy for prostate cancer - Abstract May 27, 2013

Prostate and patient intrafraction motion: Impact on treatment time-dependent planning margins for patients with endorectal balloon - Abstract May 27, 2013

Pelvic lymph node dissection during robot-assisted radical prostatectomy: Efficacy, limitations, and complications-A systematic review of the literature - Abstract May 27, 2013

Locally advanced and metastatic prostate cancer treated with intermittent androgen monotherapy or maximal androgen blockade: Results from a randomised phase 3 study by the South European Uroncological Group - Abstract May 27, 2013

Monitoring brain activation changes in the early postoperative period after radical prostatectomy using fMRI - Abstract May 27, 2013

Prostatic swelling and shift during high-intensity focused ultrasound: Implication for targeted focal therapy - Abstract May 27, 2013

The effect of anterior proton beams in the setting of a prostate-rectum spacer - Abstract May 25, 2013

Necessity analysis of bone scan in patients with newly diagnosed prostate cancer - Abstract May 25, 2013

High dose rate prostate brachytherapy - Abstract May 25, 2013

Prostate cancer diagnosis: Multiparametric MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy--Prospective multicenter study - Abstract May 24, 2013

5-Alpha reductase inhibitors in patients on active surveillance: Do the benefits outweigh the risk? - Abstract May 24, 2013

(11)C-Choline PET/CT and PSA kinetics - Abstract May 24, 2013

Cabazitaxel for the second-line treatment of metastatic hormone-refractory prostate cancer: A NICE single technology appraisal - Abstract May 24, 2013

Estrogen receptor beta expression and androgen receptor phosphorylation correlate with poor clinical outcome in hormone-naive prostate cancer and are elevated in castration resistant disease - Abstract May 24, 2013

Diabetes mellitus and prostate cancer risk; a nationwide case-control study within PCBASE Sweden - Abstract May 24, 2013

Antimitotic agents for the treatment of patients with metastatic castrate-resistant prostate cancer - Abstract May 24, 2013

BJUI Mini Reviews - Prostate angiosarcoma: Is there any association with previous radiation therapy? May 24, 2013

Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100) - Abstract May 23, 2013

Page 1157 of 1436